...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >INCIDENCE AND RISK FACTORS OF RENAL IMPAIRMENT IN HIV-1 INFECTED PATIENTS RECEIVING TENOFOVIR BASED ANTIRETROVIRAL THERAPY IN A SOUTH INDIAN HOSPITAL
【24h】

INCIDENCE AND RISK FACTORS OF RENAL IMPAIRMENT IN HIV-1 INFECTED PATIENTS RECEIVING TENOFOVIR BASED ANTIRETROVIRAL THERAPY IN A SOUTH INDIAN HOSPITAL

机译:在南印度洋医院接受以替诺福韦为基础的抗病毒治疗的HIV-1感染患者中肾功能损害的发生率和风险因素

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To identify the incidence and risk factors of tenofovir (TDF) induced nephrotoxicity among People Living with HIV/AIDS (PLHA) receiving TDF-based anti-retroviral therapy (ART) in a South Indian Hospital. Methods: A retrospective cohort study was conducted among HIV-infected ART na?ve patients taking TDF as part of either a first-line or second-line ART between July 2013 and June 2015 at Asha kirana Hospital Mysore, India. Results: A total of 380 patients have been initiated on TDF-based ART. Out of these, 335 patients were on tenofovir+lamivudine+efavirenz, 30 patients were on the tenofovir+lamivudine+nevirapine regimen and 25 patients were on tenofovir+lamivudine+atazanavir/ritonavir regimen. Renal impairment was documented for 35 patients with 9.21% incidence. 34% of renal impaired patients had a severe impairment with eGFR61 y) had higher chances of developing TDF toxicity compared to adult patients (P=0.0018). Other possible risk factors for TDF-induced renal impairment was CD4>200 (P=0.003). TDF was withdrawn and substituted with Nucleoside Reverse Transcriptase Inhibitor (NRTI) drug following the diagnosis of renal impairment. Conclusion: TDF-associated renal impairment was not uncommon in real-life practice and considered as a frequent complication during treatment with TDF. Risk factors for developing renal impairment include increasing age and CD4>200 cells.
机译:目的:确定在南印度医院接受基于TDF的抗逆转录病毒疗法(ART)的HIV / AIDS感染者(PLHA)替诺福韦(TDF)引起的肾毒性的发生率和危险因素。方法:回顾性队列研究于2013年7月至2015年6月在印度迈索尔的Asha kirana医院对接受TDF作为一线或二线ART的一部分的HIV感染ART初治患者进行。结果:共有380例患者开始使用基于TDF的抗逆转录病毒疗法。其中335例接受替诺福韦+拉米夫定+依法韦仑治疗,30例接受替诺福韦+拉米夫定+奈韦拉平治疗,25例接受替诺福韦+拉米夫定+阿扎那韦/利托那韦治疗。记录了35名患者的肾功能不全,发生率为9.21%。与成人患者相比,有34%的肾功能不全患者患有eGFR61严重损伤,发生TDF毒性的机会更高(P = 0.0018)。 TDF引起的肾功能损害的其他可能危险因素是CD4> 200(P = 0.003)。在诊断出肾功能不全后,撤回TDF并用核苷逆转录酶抑制剂(NRTI)药物代替。结论:TDF相关的肾功能障碍在现实生活中并不罕见,被认为是TDF治疗期间的常见并发症。发生肾功能不全的危险因素包括年龄增长和CD4> 200细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号